Charles River Laboratories International, Inc. (CRL): Depreciation & Amortization
$403.31M
Year ended 2025-12-27
$297.88M
Trailing 12 months to 2026-06-27
+9.9%
3-year compound annual growth
+11.4%
5-year compound annual growth
+15.6%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-27 | $403.31M | +11.5% | 2026-02-18, From 2024-12-29 |
| 2024-12-28 | $361.74M | +15.2% | 2026-02-18, From 2023-12-31 |
| 2023-12-30 | $314.12M | +3.4% | 2026-02-18, From 2023-01-01 |
| 2022-12-31 | $303.87M | +14.4% | 2025-02-19, From 2021-12-26 |
| 2021-12-25 | $265.54M | +13.0% | 2024-02-14, From 2020-12-27 |
| 2020-12-26 | $234.92M | +18.6% | 2023-02-22, From 2019-12-29 |
| 2019-12-28 | $198.09M | +22.4% | 2022-02-16, From 2018-12-30 |
| 2018-12-29 | $161.78M | +23.3% | 2021-02-17, From 2017-12-31 |
| 2017-12-30 | $131.16M | +3.6% | 2020-02-11, From 2017-01-01 |
| 2016-12-31 | $126.66M | +33.5% | 2019-02-13, From 2015-12-27 |
| 2015-12-26 | $94.88M | -1.6% | 2018-02-13, From 2014-12-28 |
| 2014-12-27 | $96.44M | -0.2% | 2017-02-14, From 2013-12-29 |
| 2013-12-28 | $96.64M | +18.9% | 2016-02-12, From 2012-12-30 |
| 2012-12-29 | $81.28M | -4.6% | 2015-02-17, From 2012-01-01 |
| 2011-12-31 | $85.23M | -9.0% | 2014-02-25, From 2010-12-26 |
| 2010-12-25 | $93.65M | +4.1% | 2013-02-27, From 2009-12-27 |
| 2009-12-26 | $89.96M | +3.6% | 2012-02-27, From 2008-12-28 |
| 2008-12-27 | $86.85M | n/a | 2011-02-23, From 2007-12-30 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $403.31M | +11.5% |
| Incyte Corp (INCY) | 2025-12-31 | $93.29M | +4.5% |
| Icon PLC (ICLR) | 2025-12-31 | $383.00M | -21.6% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $1.14B | +2.7% |
| NRC Health (NRC) | 2025-12-31 | $7.62M | +26.6% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $4.34M | +0.6% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $21.75M | -7.8% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $597.4K | -51.6% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $504.8K | -16.6% |
Compare CRL, INCY, ICLR, IQV side by side · Screen every company in Services-Commercial Physical & Biological Research ↗